Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Sévaux, R. G. L.
Right arrow Articles by Wetzels, J. F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Sévaux, R. G. L.
Right arrow Articles by Wetzels, J. F. M.
J Am Soc Nephrol 13:1608-1614, 2002
© 2002 American Society of Nephrology

Treatment with Vitamin D and Calcium Reduces Bone Loss after Renal Transplantation: A Randomized Study

Ruud G. L. de Sévaux*, Andries J. Hoitsma*, Frans H. M. Corstens{dagger} and Jack F. M. Wetzels*

Departments of *Nephrology and {dagger} Nuclear Medicine, University Medical Center Nijmegen, Nijmegen,The Netherlands.

Correspondence to Dr. R. G. L. de Sévaux, Department of Nephrology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Phone: 31-24-3614761; Fax: 31-24-3540022; E-mail: r.desevaux{at}nefro.azn.nl

ABSTRACT. A decrease in bone mineral density (BMD) is a major complication of renal transplantation (RTx), predominantly occurring within the first 6 mo after RTx. The most important causative factor is the use of corticosteroids, but persisting hyperparathyroidism and abnormalities in vitamin D metabolism play a role too. This study examines the effect of treatment with calcium and active vitamin D on the loss of BMD in the first 6 mo after RTx. A total of 111 renal transplant recipients (65 men, 46 women; age, 47 ± 13 yr) were randomized to either treatment with active vitamin D (0.25 µg/d) plus calcium (1000 mg/d) (CaD group), or to no treatment (NoT group). Immunosuppressive therapy consisted of cyclosporine, prednisone, and mycophenolate mofetil. Laboratory parameters and BMD (lumbar spine and hip) were measured at 0, 1 (laboratory only), 3, and 6 mo after RTx. Lumbar BMD was nearly normal at the time of RTx. In both groups, a significant decrease in lumbar BMD was observed during the first 3 mo (CaD, -3.3 ± 4.3%; P < 0.0001; NoT, -4.1 ± 4.8%; P < 0.0001). Between the third day and sixth month, lumbar BMD slightly recovered in the CaD group, but it decreased further in the NoT group (total loss 0 to 6 mo: CaD, -2.6 ± 5.0% [P < 0.001]; NoT, -5.0 ± 4.7% [P < 0.0001]). As a result, the amount of bone loss at 6 mo was significantly lower in the CaD group (P = 0.02). Loss of BMD at the different femoral sites was also significantly reduced in the CaD group. Apart from a trend toward more frequent hypercalcemia in the CaD group, no clinical or biochemical differences existed between the groups. Treatment with a low dose of active vitamin D and calcium partially prevents bone loss at the lumbar spine and proximal femur during the first 6 mo after RTx.




This article has been cited by other articles:


Home page
 CJASNHome page
J. R. Weisinger, R. G. Carlini, E. Rojas, and E. Bellorin-Font
Bone Disease after Renal Transplantation
Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1300 - 1313.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673